Ohio State Navbar

Specialty Programs

Research


We have an active research program to bring you the latest treatments and innovative approaches.  Below are the active studies for which we are actively enrolling patients.

Please
contact us if you would like more information regarding any of the trials listed below or if you have any other questions pertaining to pulmonary hypertension research at OSU.

Protocol Name: Effects of combination of bosentan and sildenafil versus sildenafil monotherapy on morbidity and mortality in symptomatic patients with pulmonary arterial hypertension - A multicenter, double-blind, randomized, placebo-controlled, parallel group, prospective, event driven Phase IV study
Sponsor: Actelion
PI:  Namita Sood, MD
Coordinator: Jessica Smith
Synopsis:  The purpose of this study is to evaluate how safe and how effective bosentan is in combination with sildenafil.  The combination use will be compared to subjects receiving sildenafil only.  Potential subjects will be patients using sildenafil for the treatment of pulmonary arterial hypertension (PAH) who still have symptoms.

Protocol Name:  A 12-Week, International, Multicenter, Double Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT 15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension
Sponsor: United Therapeutics
PI:  Namita Sood, MD
Coordinator:  Jessica Smith
Synopsis:  The purpose of this research study is to determine if UT 15C SR will help control the symptoms of PAH and determine if it is safe.
 
Protocol Name:  A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension
Sponsor:  Actelion
PI:  Namita Sood, MD
Coordinator:  Jessica Smith
Synopsis:  The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug, ACT-064992, when used to treat pulmonary arterial hypertension. 

Protocol Name:  A Randomized, Multicenter Study of Ambrisentan and Sildenafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension who have Demonstrated a Sub-Optimal Response to Sildenafil
Sponsor:  Gilead
PI:  Namita Sood, MD
Coordinator:  Jessica Smith
Synopsis:  This research study will evaluate the combination of ambrisentan and sildenafil. 

Protocol Name:  A Phase IIIb, multicenter, open-label study of patients with pulmonary arterial hypertension treated with iloprost (inhalation) evaluating safety and inhalation times when converting from power disc-6 to power disc-15 with the I-NebĀ® AAD
Sponsor:  Actelion
PI:  Namita Sood, MD
Coordinator:  Jessica Smith
Synopsis:  The purpose of this research study is to test the safety and tolerability of a new disc, the Power Disc-15 (PD-15) compared to the approved disc, the Power Disc-6 (PD-6). 


Protocol:  A Multicenter, Double-blind, Randomized Study comparing the Safety and Tolerability of Iloprost inhalation solution delivered by I-neb utilizing Power disc-15 and Power disc-6 in Patients with Symptomatic Pulmonary Arterial Hypertension
Sponsor:  Actelion
PI:  Namita Sood, MD
Coordinator:  Jessica Smith
Synopsis:  The main purpose of this clinical research is to compare the safety and tolerability of VentavisĀ®, using the new power 15 disc and approved power 6 disc up to 12 weeks in subjects with Pulmonary Arterial Hypertension. 

Protocol:  A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension
Sponsor:  Actelion
PI:  Namita Sood, MD
Coordinator:  Jessica Smith
Synopsis:  The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug, ACT-064992, when used to treat pulmonary arterial hypertension. 

Protocol:  Long-term, single-arm, open label extension study of the SERAPHIN study, to assess the safety and tolerability of ACT 064992 in patients with symptomatic pulmonary arterial hypertension
Sponsor:  Actelion
PI:  Namita Sood, MD
Coordinator:  Jessica Smith
Synopsis:  The purpose of this research study is to test the safety, tolerability, and effectiveness of the investigational drug, ACT-064992, when used to treat pulmonary arterial hypertension

Protocol:  Randomized, double-blind, placebo-controlled, multicentre, multi national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). CHEST-1 Study
Sponsor:  Bayer Healthcare AG
PI:  Namita Sood, MD
Coordinator:  Jessica Smith
Synopsis:  The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug, BAY 63-2521, when used to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH). 

Protocol:  Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)- PATENT-1 Study
Sponsor:  Bayer Healthcare AG
PI:  Namita Sood, MD
Coordinator:  Jessica Smith
Synopsis:  The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug, BAY 63-2521, when used to treat pulmonary arterial hypertension (PAH). 

Protocol:  The expression and significance of miRNA profile and markers of inflammation in patients with pulmonary arterial hypertension
Sponsor:  Pulmonary Division
PI:  Namita Sood, MD
Coordinator:  Jessica Smith
Synopsis:  This study is being done to see if blood samples can be tested to determine who might develop PAH, how well drugs will work to treat PAH and to learn more about the development of PAH.